The $0.10 Wonder Drug
Metformin activates AMPK (AMP-activated protein kinase), the body's energy sensor. When AMPK is activated, cells shift from growth mode to maintenance mode — improving insulin sensitivity, reducing inflammation, enhancing autophagy, and improving mitochondrial function. These are the same pathways targeted by caloric restriction, exercise, and rapamycin.
The Epidemiological Evidence
A 2014 UK study analyzed 180,000 people over 13 years and found type 2 diabetics taking metformin had a 15% lower mortality rate than non-diabetic controls. This is extraordinary — diabetes shortens lifespan by 6-8 years, yet diabetics on metformin outlived healthy non-diabetics.
The TAME Trial
The TAME (Targeting Aging with Metformin) trial, led by Nir Barzilai at Albert Einstein College of Medicine, will enroll 3,000 adults ages 65-79 and track whether metformin delays age-related diseases. If successful, it would be the first time the FDA recognizes "aging" as a treatable condition — a regulatory precedent that would transform longevity drug development.
